Protective effect of N-acetylcysteine on INH-induced hepatotoxicity in patients with latent TB.

Protective effect of N-acetylcysteine on INH-induced hepatotoxicity in patients with latent TB (Randomized Clinical trial).

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200328046886N4

Enrollment

Registered

2021-10-03

Start date

2021-09-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Latent tuberculosis. Latent tuberculosis

Interventions

Intervention 1: Intervention group: Patients diagnosed with latent Tuberculosis will be treated with Isoniazid for a period of 6-9 months. NAC tablets will be administrated along with Isoniazid for 4

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with latent tuberculosis using tuberculin skin test or IGRA.

Exclusion criteria

Exclusion criteria: Liver disease Active tuberculosis hepatitis Pregnansy Lactating Alcoholism Sensitivity to NAC

Design outcomes

Primary

Measure	Time frame
Age. Timepoint: The beginning of the study. Method of measurement: questionnaire.;Sex. Timepoint: The beginning of the study. Method of measurement: questionnaire.;AST. Timepoint: The beginning ,first ,second,forth ,sixth, eighth weeks of the study. Method of measurement: Labrotory.;ALT. Timepoint: The beginning ,first ,second,forth ,sixth, eighth weeks of the study. Method of measurement: Labrotory.;Drug side effects. Timepoint: Start until the end of the study. Method of measurement: questionnaire.;ALP. Timepoint: The beginning and end of the study. Method of measurement: Labratory.;Bilirubin total. Timepoint: The beginning and end of the study. Method of measurement: Labratory.	—

Measure

Time frame

Age. Timepoint: The beginning of the study. Method of measurement: questionnaire.;Sex. Timepoint: The beginning of the study. Method of measurement: questionnaire.;AST. Timepoint: The beginning ,first ,second,forth ,sixth, eighth weeks of the study. Method of measurement: Labrotory.;ALT. Timepoint: The beginning ,first ,second,forth ,sixth, eighth weeks of the study. Method of measurement: Labrotory.;Drug side effects. Timepoint: Start until the end of the study. Method of measurement: questionnaire.;ALP. Timepoint: The beginning and end of the study. Method of measurement: Labratory.;Bilirubin total. Timepoint: The beginning and end of the study. Method of measurement: Labratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamideh Abbaspour Kasgari

Mazandaran University of Medical Sciences

dr.abbaspour1@yahoo.com+98 11 4203 1035

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026